Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. reported that it has completed enrollment and dosing in its Phase 3 clinical trial of LPCN 1154 for postpartum depression. This means all planned participants have entered the study and received the investigational treatment, marking a key operational milestone for the program. The update was shared through a press release, which is included as an exhibit to this report.
Lipocine Inc. filed a current report stating that it has updated the corporate presentation it uses in meetings with investors, analysts, and other audiences. The updated presentation is included as Exhibit 99.1 to the report, making the materials publicly available through the SEC system. This filing does not announce a specific transaction or financial results, but formally records that new investor presentation materials are now on file.
Lipocine Inc. filed a report describing clinical progress for its investigational drug LPCN 1154 in postpartum depression. On January 12, 2026, the company issued a press release stating there was encouraging progress following the second interim safety review in its Phase 3 trial of LPCN 1154. The press release is provided as an exhibit to the report and is incorporated by reference.
Lipocine Inc. filed a current report to share progress on its clinical development program. On December 16, 2025, the company issued a press release stating that Lipocine’s PPD Phase 3 Study (LPCN 1154) has reached 80% enrollment. This means most of the planned participants for the Phase 3 clinical study have been enrolled, marking a notable step toward completing patient recruitment.
The press release describing this enrollment milestone is furnished as Exhibit 99.1, while a cover page interactive data file is included as Exhibit 104. Lipocine’s common stock, with par value $0.0001 per share, trades on the Nasdaq Stock Market under the symbol LPCN.
Lipocine Inc. reported that board member Jeffrey Fink has informed the Board of Directors that he will resign from the board effective January 1, 2026, for personal reasons. The company states that his resignation is not the result of any disagreement with the company on any matter, which suggests no underlying dispute or conflict is driving the change. The board plans to conduct a search for a new director to fill the upcoming vacancy.
Lipocine Inc. reported that it presented scientific posters on its epilepsy drug candidate LPCN 2101 at the American Epilepsy Society Annual Meeting in Atlanta. The company highlighted clinical pharmacokinetics and tolerability data for this novel oral GABA A receptor positive allosteric modulating candidate for epilepsy, along with oral toxicokinetics data for a bioidentical GABA A receptor modulating neuroactive steroid anti-seizure medication candidate for women with epilepsy.
The posters are furnished as Exhibits 99.1 and 99.2 to the report, giving readers more detail on how LPCN 2101 behaves in the body and how well it was tolerated in the studies described.
Lipocine Inc. (LPCN) filed a current report to announce that it has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders. The updated materials are being made publicly available as Exhibit 99.1 to this report. By filing the presentation, the company is providing broader market access to the same information it shares in its investor meetings.
Lipocine Inc. (LPCN) reported that it has issued a press release highlighting a promising interim safety profile for its investigational drug LPCN 1154 in a Phase 3 clinical trial for postpartum depression (PPD). The company describes these findings as interim safety results, meaning the study is still ongoing but, so far, the treatment has shown a favorable safety profile in participants.
The press release containing more detail is furnished as Exhibit 99.1 to this report and is incorporated by reference, while no specific efficacy data or numerical safety outcomes are provided in this summary. The update signals continued clinical progress of LPCN 1154 in a late-stage trial targeting postpartum depression, a serious mood disorder affecting women after childbirth.
Lipocine Inc. (LPCN) furnished an 8-K announcing it issued a press release with financial and operational results for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and incorporated by reference. The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act.
Lipocine Inc. reported Q3 2025 results, highlighting modest royalty revenue and higher R&D investment as it advances its pipeline. Revenue was $114,574 for the quarter, driven by royalties, with nine‑month revenue of $831,287. The company posted a Q3 net loss of $3,186,832 and a nine‑month net loss of $7,257,421.
Cash and cash equivalents were $3,901,040 and marketable investment securities were $11,230,031 as of September 30, 2025. Management states existing capital resources are expected to fund operations through at least November 6, 2026. Stockholders’ equity was $14,142,048. Shares outstanding were 5,551,931 as of November 5, 2025.
Commercial progress continued under the Verity license for TLANDO, with Q3 royalty revenue of approximately $115,000 and a Canadian NDS filed in June 2025. Year‑to‑date, licensing revenue was $500,000 and royalty revenue was approximately $331,000, reflecting a shift from prior‑year upfront license income. R&D expenses rose to $2,707,777 in Q3, while G&A declined to $767,837. The company also sold 68,691 shares via its ATM program for net proceeds of $217,000 year‑to‑date.